Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR00208 + bendamustine versus rituximab + bendamustine in relapsed or refractory diffuse large B-cell lymphoma not eligible for HDC/ASCT
2014-004689-11Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by MorphoSys AG. Primary endpoint: progression-free survival. Started Apr 2016; status: completed.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2014-004689-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004689-11.